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1 |  INTRODUCTION
Primary liver cancer accounts for more than 30 000 deaths 
each year in Japan and is one of the leading causes of cancer 
death worldwide.1 Hepatocellular carcinoma (HCC) is the 
most prevalent subtype of primary liver cancer.1 Despite sig-
nificant advances in HCC treatment, the recurrence rate is 
still high at 60%‐70%.2,3 Thus, increasing attention is being 
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Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death world-
wide. Cancer stem cells (CSCs) have attracted attention as a novel therapeutic target 
for cancer because they play important roles in the development and aggravation of 
cancer. CD44 is expressed as a standard isoform (CD44s) and several variant iso-
forms. CD44v is a major isoform expressed on CSCs of a variety of tumors and has 
been extensively studied. However, HCC tissues dominantly express CD44s, whose 
function in CSCs remains unclear. In the present study, we investigated the roles of 
CD44s in CSCs of HCC. Knock‐out of the CD44 gene in HuH7 HCC cells on which 
only CD44s is expressed resulted in decreased spheroid formation and increased 
drug sensitivity. The expression of CSC marker genes, including CD133 and 
EpCAM, was significantly downregulated in the spheroids of CD44‐deficient cells 
compared with those in the spheroids of HuH7 cells. In addition, CD44 deficiency 
impaired antioxidant capacity, concomitant with downregulation of glutathione per-
oxidase 1 (GPX1) and thioredoxin. Because GPX1 uses the reduced form of glu-
tathione (GSH) to regenerate oxidized cellular components, GSH levels were 
significantly increased in the CD44‐deficient cells. We also found that NOTCH3 and 
its target genes were downregulated in the spheroids of CD44‐deficient cells. 
NOTCH3 expression in HCC tissues was significantly increased compared with that 
in adjacent nontumor liver tissues and was correlated with CD44 expression. These 
results suggest that CD44s is involved in maintenance of CSCs in a HCC cell line, 
possibly through the NOTCH3 signaling pathway.
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focused on the mechanisms by which cancer cells acquire the 
malignant phenotype.
Accumulating evidence suggests that recurrence and me-
tastasis in many cancers can be attributed to cancer stem cells 
(CSCs).4,5 Because CSCs have the ability of self‐renewal 
and differentiation, CSCs are indispensable for initiating and 
maintaining tumor phenotypes while other cancer cells (non‐
CSCs) do not have such properties.6 The existence of CSCs 
was first demonstrated in acute myeloid leukemia.7 Since 
then, using specific CSC markers, the existence of CSCs has 
been proven in various tumors such as brain, breast, lung, 
colon, and liver.8-12 Several studies reported that liver CSCs 
express several markers such as epithelial adhesion molecule 
(EpCAM), CD13, CD44, and/or CD133 and that the expres-
sion of these molecules on HCC cells is correlated with poor 
prognosis.12-14 Because CSCs display the features of tumor-
igenicity and resistance to conventional chemotherapy and 
radiotherapy, it is suggested that surviving CSCs eventually 
cause tumor recurrence and metastasis although conventional 
therapies could eliminate non‐CSCs.4,5 Therefore, the re-
moval of CSCs is important to cure cancer completely.
A transmembrane glycoprotein CD44 is the most fre-
quently observed CSC marker.15 The gene encoding human 
CD44 consists of 20 exons, 10 of which are variant exons, 
and produces several isoforms.16 The CD44 variant isoform 
containing the variant exons 8 and 10 (CD44v) is a major 
CSC marker, and frequently upregulated on CSCs of many 
tumors such as gastric, colorectal, breast, and prostate can-
cers.17 Because this isoform promotes glutathione (GSH) 
synthesis by interacting with xCT, a glutamate‐cystine trans-
porter, CD44v enhances antioxidant capacity in CSCs.18 In 
contrast, the CD44 standard isoform (CD44s) lacking variant 
exons is found in various cells such as mesenchymal stromal 
and hematopoietic cells.19 However, it has been reported that 
hepatic CSCs dominantly express CD44s and that CD44s is 
involved in epithelial mesenchymal transition (EMT).20-22 
We have previously reported that CD44 expression in HCC 
tissues, which is assessed by an antibody against total CD44, 
was significantly associated with poor prognosis while no 
significant association was observed between the prognosis 
and CD44v expression, which is assessed by a CD44v‐spe-
cific antibody.23 These results prompted us to investigate the 
biological functions of CD44s in controlling antioxidant ca-
pacity and CSCs in HCC.
Genome editing technologies are widely used for inves-
tigating molecular functions of gene products.24 Clustered 
regularly interspaced short palindromic repeats/CRISPR‐as-
sociated proteins 9 (CRISPR/Cas9) system is one of the most 
established genome editing technologies derived from pro-
karyotes, where this system plays a role as an immune system 
against phages and plasmids.25,26 Cas9 is an endonuclease and 
cleaves a specific DNA sequence indicated by a guide RNA 
at a position 3‐bp upstream of the trinucleotide (5′‐NGG‐3′) 
protospacer‐adjacent motif (PAM).24 Mutation(s) is thought 
to be induced during a DNA repair process known as non-
homologous end joining.24 The CRISPR/Cas9 system has 
proven its applicability for cancer research.27 This prompted 
us to study the function of CD44s in HCC cells.
In this study, we established CD44‐knocked out (CD44‐
KO) cells from human HuH7 HCC cells, in which only 
CD44s is expressed, by means of the CRISPR/Cas9 system, 
and investigated the phenotypic changes in CSC properties of 
CD44‐KO cells.
2 |  MATERIALS AND METHODS
2.1 | Knocking out the CD44 gene in HuH7 
cells
Human hepatocellular carcinoma HuH7, HLE, HLF, HuH6, 
PLC/PRF/5, and HepG2 were purchased from the JCRB cell 
bank (Osaka, Japan) and was maintained in DMEM (Nissui 
Pharmaceutical; Tokyo, Japan) supplemented with 10% inac-
tivated FBS (Sigma‐Aldrich; St. Louis, MO, USA).
Single‐guide RNA (sgRNA) targeting the CD44 gene 
was designed by GeneArt CRISPR Search and Design 
Tool (https://apps.thermofisher.com/apps/crispr/index.
html), crispr grna design tool (https://www.atum.bio/
eCommerce/cas9/input) and CRISPRdirect (https://crispr.
dbcls.jp/). Off‐target sequence was searched by using 
GGGenome (https://gggenome.dbcls.jp/en/). The sequence 
CTACAGCATCTCTCGGACGGAGG (underline indicates 
PAM sequence) commonly provided by all three programs 
was used as the sgRNA. A double‐stranded oligo DNA har-
boring the sequence (Table S1) was ligated into pSpCas9(B-
B)‐2A‐GFP (PX458) (Addgene, #48138; Cambridge, MA, 
USA), which expresses both sgRNA and SpCas9.24 The 
plasmid DNA was transfected into HuH7 cells with Viofectin 
(Viogene, New Taipei City, Taiwan). It is of note that the cells 
used for the transfection was not sorted and thereby included 
both CD44‐positive and negative cells. Sequencing analy-
sis of the genomic DNA of independent clones obtained by 
limited dilution was performed by BigDye Terminator v3.1 
Cycle Sequencing Kit (Thermo Fisher Scientific; Waltham, 
MA, USA). The HuH7 HCC cells in which the CD44 gene is 
knocked out were designated CD44‐KO cells.
2.2 | Spheroid formation assay
HuH7 or CD44‐KO cells were plated in a ultra‐low at-
tachment 24‐well plate (Corning; Corning, NY, USA) at 
3000 cells/well and were cultured for 7 days in a spheroid 
culture medium, which was prepared by adding 20 ng/mL of 
recombinant human epidermal growth factor (PeproTech; 
Rocky Hill, NJ, USA), 20 ng/mL of recombinant human 
basic fibroblast growth factor (PeproTech), 1 × B27 
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(Thermo Fisher Scientific), and 0.52% methylcellulose 
(Sigma‐Aldrich), to Ham's F‐12 medium (Nacalai Tesque; 
Kyoto, Japan). The number of spheroids was counted by 
ImageJ software (Bethesda, MD, USA). NOTCH3‐specific 
siRNAs (siN3‐1 and siN3‐2) (Silencer Select siRNA s9640 
and s532202, respectively, Thermo Fisher Scientific) and 
negative control siRNA (siNC) (Silencer Select Negative 
Control No. 2 siRNA, Thermo Fisher Scientific) were 
transfected with Lipofectamine RNAiMax (Thermo Fisher 
Scientific) into HuH7 cells one day before the start of sphe-
roid culture.
2.3 | Reverse transcription quantitative 
PCR (RT‐qPCR)
Cells in monolayer culture were prepared by culturing 
HuH7 or CD44‐KO cells at 6.5 × 104 cells/well in a 12‐
well cell culture plate (Violamo; Osaka, Japan) for 4 days. 
Spheroids were prepared by plating cells at 5.0 × 104 cells/
well in the ultra‐low attachment 24‐well plate, and cultur-
ing the cells in the spheroid culture medium for 7 days. 
Total RNA was recovered by TRIzol (Thermo Fisher 
Scientific). Following treatment with DNase (Nippon 
Gene; Tokyo, Japan), complementary DNA was synthe-
sized by Super Script First‐Strand Synthesis for RT‐PCR 
Kit (Thermo Fisher Scientific). QPCR was performed by 
THUNDERBIRD SYBR qPCR Mix (Toyobo, Otsu, Japan) 
using ViiA 7 Real‐time PCR System (Thermo Fisher 
Scientific). Primers used in the present study were summa-
rized in Table S1. Relative mRNA expression levels were 
calculated by using β‐actin as an internal control. For com-
parison of monolayer culture and spheroids, HPRT1 was 
used as an internal control instead of β‐actin, whose expres-
sion level was readily affected by the culture conditions.
2.4 | Western blot analysis
Cells in monolayer culture were incubated in a 6‐cm dish 
(Violamo) at 5.0 × 105 cells/dish for 4 days. Spheroids 
were prepared by seeding cells to a Sumilon PrimeSurface 
90‐mm dish (Sumitomo Bakelite; Tokyo, Japan) at 
1.0 × 106 cells/dish and incubated in spheroid culture me-
dium for 7 days. The cells were washed three times with 
phosphate‐buffered saline and were lysed in 150 µL RIPA 
buffer (50 mmol/L Tris‐HCl (pH 7.9), 150 mmol/L NaCl, 
1% NP‐40, 0.5% sodium deoxycholate, 0.1% sodium do-
decyl sulfate (SDS)). After freezing the lysate at −80°C, 
the protein concentration was determined by the Bradford 
reagent (Bio‐Rad Laboratories; Hercules, CA, USA) and 
was adjusted with the RIPA buffer and 5 × sample buffer 
(60 mmol/L Tris‐HCl (pH 7.9), 14.4% β‐mercaptoethanol, 
2% SDS, 25% glycerol). SDS‐polyacrylamide gel electro-
phoresis and immunoblotting were performed by standard 
procedures. Antibodies against actin (sc‐1616; Santa Cruz 
Biotechnology; Dallas, TX, USA), CD44 (#3570; Cell 
Signaling Technology; Danvers, MA, USA), glutathione 
peroxidase 1 (GPX1) (ab22604; Abcam; Cambridge, UK), 
glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH) 
(sc‐365062; Santa Cruz Biotechnology), NOTCH1‐3 
(#3608, #5732, and #5276, respectively; Cell Signaling 
Technology), superoxide dismutase 1 (SOD1) (sc‐11407; 
Santa Cruz Biotechnology), and thioredoxin (TXN) 
(M013‐3; MBL; Nagoya, Japan) were used.
2.5 | Determination of cellular reactive 
oxygen species
Cellular reactive oxygen species were measured by using 
DCFDA‐Cellular Reactive Oxygen Species Detection Assay 
Kit (Abcam) with slight modifications. Cells were seeded 
to a dark 96‐well microplate (Thermo Fisher Scientific) at 
1 × 104 cells/well and were allowed to attach overnight. The 
cells were washed twice with 1 × buffer solution and were 
incubated with 100 µL of DCFDA solution for 45 minutes at 
37°C. After being washed twice with 1 × buffer solution, the 
cells were exposed to 0, 50, or 100 µmol/L of hydrogen per-
oxide (H2O2) (Nacalai Tesque) or tert‐butyl hydroperoxide 
(TBHP) (Abcam) for 5 hours at 37°C. Fluorescence intensity 
(excitation, 485 nm; emission, 535 nm) was measured by a 
plate reader (Tecan; Männedorf, Switzerland).
2.6 | Determination of cellular GSH content
GSH and GSSG (oxidized glutathione) in cells at a conflu-
ency of approximately 80% on a 10‐cm dish were determined 
by GSH/GSSH Quantification Kit (Dojindo; Kumamoto, 
Japan) according to the manufacturer’s protocol. Absorbance 
at 415 nm was measured by using the plate reader.
T A B L E  1  Clinical and demographic characteristics of 
hepatocellular carcinoma patients
Number of patients 92
Age (y) 67.2 ± 10.7a
Gender (male/female) 79/13
Etiology (HBV/HCV/nonB·nonC) 40/23/29
Child‐Pugh score (5/6/≥7) 67/19/6
Number of tumors (1/≥2) 80/13
Tumor size (cm) 5.3 ± 4.1a
vp (0/1/2/3/NA) 64/19/4/2/3
TNM stage (IA/IB/II/IIIA/IIIB/IVA) 8/30/38/7/7/2
Fibrosis stage (HAI‐IVb) (≤3/4/NA) 61/27/4
Survival period (y) 4.2 [2.8‐7.3]c
aMean ± standard deviation. 
bHistological activity index IV (Ishak K, et al J Hepatol. 1995;22:696‐699). 
cMedian [interquartile range]. 
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2.7 | Cell viability assay
Cells were seeded to a 96‐well plate (Violamo) at 
5.0 × 103 cells/well and were allowed to attach overnight. 
The cells were treated with 0‐20 µmol/L of sorafenib (Bayer; 
Leverkusen, Germany), or 0‐50 µg/mL of 5‐fluorouracil 
(5‐FU) (Nacalai Tesque) for 72 hours. The concentration of 
solvent (dimethyl sulfoxide) was kept at 0.1%. Cell counting 
kit‐8 (Dojindo) was used to determine cell viability accord-
ing to the manufacturer’s protocol. Absorbance at 450 and 
600 nm was measured by using the plate reader.
2.8 | Analysis of human samples
Liver specimens from 92 HCC patients (Table 1) were ob-
tained at Tottori University Hospital between 2004 and 2013 
and immediately stored in RNAlater (Qiagen; Valencia, 
CA, USA) at −80°C. RNA from frozen specimens was re-
covered and purified using TRIzol reagent and RNeasy Plus 
Kit (Qiagen), according to the manufacturer’s instructions. 
CDNA synthesis and quantitative RT‐PCR were performed 
as described above. The clinical data of the patients were col-
lected from medical records. Medical records were reviewed 
retrospectively after approval by the Institutional Review 
Board of our institution in accordance with the ethical stand-
ards laid down in the 1964 Declaration of Helsinki and its 
later amendments (Institutional Review Board approval 
number: 18A071).
2.9 | Statistical analysis
Independent samples, of which numbers are over 3, were an-
alyzed, and all experimental values were expressed as mean 
±standard deviation (SD). The differences between the two 
groups were assessed by Student’s t test. P value <0.05 was 
considered as statistically significant.
3 |  RESULTS
3.1 | Knocking out the CD44 gene in HuH7 
cells
Since HuH7 cells express only CD44s isoform,22 we 
knocked out the CD44 gene in HuH7 cells by employing 
the CRISPR/Cas9 system to clarify whether CD44s plays 
a role in HCC. Several clones were obtained by limited 
dilution of HuH7 cells transfected with plasmid DNA 
expressing SpCas9 and sgRNA targeting the CD44 exon 
2, one of which showed 8‐bp deletion and 256‐bp inser-
tion within each CD44 allele (Figure S1). This clone also 
showed remarkable decreases in expression of mRNA and 
protein of CD44 (Figure 1A,B). No mutation was found 
in the inhibitor of nuclear factor kappa B kinase subunit 
gamma (IKBKG) gene, which is the only one gene that was 
predicted to contain a potential off‐target site by searching 
with 12‐mer plus PAM sequence (Figure S2). We hereafter 
used this clone as CD44‐KO cells.
3.2 | Lowering of antioxidant capacity in 
CD44‐KO cells
CD44v was reported to increase cellular antioxidant capac-
ity by activating the biosynthesis of GSH.18 High antioxidant 
capacity is a common feature of CSCs,18,28,29 prompting us 
to investigate the effect of CD44s deficiency on cellular anti-
oxidant capacity. CD44‐KO cells treated with H2O2 or TBHP 
showed significantly higher oxidative stress than HuH7 cells 
at 0, 50, and 100 µmol/L of their concentrations (Figure 
2A,B), suggesting that CD44s increases cellular antioxidant 
capacity in HuH7 cells.
3.3 | Decreased expression of antioxidant 
factors in CD44‐KO cells
The mRNA expression of antioxidant factors was determined 
by RT‐qPCR. In CD44‐KO cells, SOD1, TXN, GPX1, and 
GPX3 were significantly downregulated while SOD2 was 
significantly upregulated (Figure 3A). Because antioxidant 
capacity was lowered in CD44‐KO cells, we performed 
Western blotting for GPX1, TXN, and SOD1. The protein 
expression of GPX1 and TXN was markedly decreased 
while SOD1 protein expression was not changed (Figure 
3B). GPX1 is an important antioxidant enzyme reducing 
oxidized cellular components by converting reduced GSH 
to the oxidized form (GSSG).30 The cellular GSH content 
of CD44‐KO cells was significantly increased, and the ratio 
of GSH to GSSG was also higher than that of HuH7 cells 
(Figure 3C,D), suggesting the suppression of GPX1 activity 
in CD44‐KO cells.
F I G U R E  1  CD44 expression in HuH7 and CD44‐KO cells. 
A, relative mRNA expression levels of CD44 to β‐actin. *P < 0.05, 
vs HuH7 cells; Student’s t test. B, CD44 protein expression. Actin is 
shown for loading control
A B
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3.4 | Increased drug sensitivity of CD44‐
KO cells
Drug resistance is another main feature of CSCs and is ac-
quired by the high antioxidant capacity as well as by increased 
expression of drug transporters.6 As expected, CD44‐KO cells 
showed an increased sensitivity to sorafenib and 5‐FU at rela-
tively high concentrations (Figure 4), suggesting that CD44s 
is an important factor for drug resistance in HuH7 cells.
3.5 | Decreased cancer stemness of CD44‐
KO cells
Because CSCs have the ability of anchorage‐independent 
growth like normal stem cells, the spheroid culture of can-
cer cells has been employed to assess cancer stemness and 
to enrich CSCs.31 This assay showed a significant decrease 
in cancer stemness of CD44‐KO cells (Figure 5A,B). CSC 
markers including CD44, CD133, and EPCAM were signifi-
cantly upregulated in spheroids of HuH7 cells while such up-
regulation was not observed in CD44‐KO cells (Figure 5C). 
This observation suggests that CD44s is critical for maintain-
ing cancer stemness in HuH7 cells.
3.6 | Involvement of NOTCH3 in CD44‐
mediated maintenance of cancer stemness
Hedgehog, WNT/β‐catenin, and NOTCH signaling path-
ways are well‐known and important regulatory mechanisms 
to maintain cancer stemness, and either of these pathways 
F I G U R E  2  Cellular oxidative stress. A, oxidative stress in cells 
treated with 0‐100 µmol/L of H2O2 for 5 h. B, oxidative stress in cells 
treated with 0‐100 µmol/L of TBHP for 5 h. Open bars, HuH7 cells; 
filled bars, CD44‐KO cells. *P < 0.05; Student's t test
A
B
F I G U R E  3  Expression of antioxidant 
factors. A, relative mRNA expression levels 
of antioxidant factors to β‐actin. B, protein 
expression levels of GPX1, TXN, and 
SOD1. Actin is shown for loading control. 
C, cellular GSH content. D, cellular GSH to 
GSSG ratio. Open bars, HuH7 cells; filled 
bars, CD44‐KO cells. *P < 0.05, vs HuH7 
cells; Student's t test
A
B C D
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are activated in most types of CSCs.6 We determined the ex-
pression levels of target genes of hedgehog (GLI1), WNT/β‐
catenin (HNF1α, CCND1, and c‐MYC), and NOTCH 
(HES1, HEY1, and HEYL) signaling pathways by RT‐
qPCR. GLI1 was induced by the spheroid culture in HuH7 
cells (Figure 6A). The expression of GLI1 was consistently 
high in CD44‐KO cells, but significantly decreased by the 
spheroid culture. Although HNF1α and CCND1 were not 
changed, c‐MYC was significantly upregulated by the sphe-
roid culture of both cells (Figure 6A). The target genes of 
NOTCH signaling, such as HES1, HEY1, and HEYL, were 
significantly upregulated by the spheroid culture of HuH7 
cells while their expression levels in CD44KO cells were 
not changed (Figure 6A).
We next examined the expression of signaling mole-
cules of the NOTCH pathway. Among NOTCH receptors, 
only NOTCH3 showed a significant change in its expres-
sion, similar to those of the target genes (Figure 6A,B). Note 
that NOTCH4 expression was not detected in HuH7 cells. 
Other components in the NOTCH pathway were not changed 
(Figure 6C). The expression of NOTCH intracellular domain 
(NICD), which is produced by the cleavage of the NOTCH 
receptors, is a hallmark of the activation of the NOTCH sig-
naling.32 The expression of NOTCH3 NICD in HuH7 spher-
oids was higher than that in CD44‐KO spheroids (Figure 
6D). NOTCH1 and NOTCH2 by the spheroid culture were 
unlikely activated both in HuH7 and CD44‐KO cells because 
cleaved bands corresponding to their NICDs were not ob-
served (Figure S3A). In addition, siRNA‐mediated knock-
down of NOTCH3 in HuH7 cells resulted in a decrease in 
spheroid formation (Figure S3B), suggesting that NOTCH3 
is an important mediator of CD44‐mediated maintenance of 
cancer stemness in HuH7 cells.
3.7 | Possible existence of a CD44‐NOTCH3 
axis in human HCC tissue
Hepatocellular carcinoma tissues collected at Tottori 
University Hospital (Table 1) were used to determine the 
mRNA expression levels of CD44, NOTCH3, and GPX1. 
F I G U R E  4  Drug sensitivity to sorafenib and 5‐FU. A, viability 
of cells exposed to the indicated concentrations of sorafenib for 72 h. 
B, viability of cells exposed to the indicated concentrations of 5‐FU for 




F I G U R E  5  Cancer stemness. A, representative images of 
spheroids of HuH7 (upper panel) and CD44‐KO (lower) cells. scale 
bars, 150 µm. B, number of spheroids derived from HuH7 (open bar) 
and CD44‐KO (filled bar) cells. *P < 0.05, vs HuH7 cells; Student's 
t test. C, relative mRNA expression levels of CSC markers to HPRT 
White bars, HuH7 cells in monolayer culture; light gray bars, HuH7 
spheroids; gray bars, CD44‐KO cells in monolayer culture; black bars, 




   | 779ASAI et Al.
The expression of NOTCH3, but not GPX1, was signifi-
cantly correlated with that of CD44 both in the HCC tissues 
(Figure 7).
4 |  DISCUSSION
Genome editing technologies including CRISPR/Cas9 
have enabled us to knock‐out gene(s) in mammalian cells 
with high efficiency and low cost.24 It has been reported 
that NANOG‐deficient prostate cancer cells generated by 
the CRISPR/Cas9 system showed a significant decrease 
in tumorigenicity, compared with parental cells.27 Thus, 
we decided to employ this technology to study the patho-
logical roles of CD44s in liver CSCs. However, although 
around 50 clones were analyzed for CD44 exon 2 sequence 
following the introduction of the CRISPR/Cas9 vector, we 
obtained only one clone that harbors the desired mutation 
in both alleles of the CD44 gene. Given that non‐CSCs are 
deficient to form a spheroid,31 the population of CSCs in 
HuH7 cells was assumed to be approximately 0.6% based 
on our spheroid formation assay (Figure 5B). This assump-
tion suggests that the CD44 gene is expressed in only a 
small number of HuH7 cells. Because the targeting effi-
ciency of transcriptionally inactive genes by CRISPR/Cas9 
is low, additional treatment such as valproic acid may be 
necessary to enhance the knock‐out efficiency, in particu-
lar, of CSC marker genes.33
Off‐target effects are a disadvantage of the CRISPR/Cas9 
system that needs to be considered, especially when knock‐
out efficiency is low. Target specificity is determined mainly 
by a seed sequence within 12‐nt from the PAM since the 
F I G U R E  6  Relative mRNA expression of signaling factors to HPRT. A, hedgehog (GLI1), WNT/β‐catenin (HNF1α, CCND1, and c‐MYC), 
and NOTCH (HES1, HEY1, and HEYL) signaling pathways. B, NOTCH ligands. C, NOTCH signaling factors. White bars, HuH7 cells in 
monolayer culture; light gray bars, HuH7 spheroids; gray bars, CD44‐KO cells in monolayer culture; black bars, CD44‐KO spheroids. *P < 0.05, 
monolayer vs spheroids; Student’s t test. D, Western blotting of cleaved transmembrane/intracellular fragment (NTM) and intracellular domain 
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introduction of a mutation into this region impaired specific 
cleavage by CRISPR nuclease.25,26 Thus, we searched for po-
tential off‐target genes by 12‐nt + PAM using an online pro-
gram, by which only one gene, IKBKG was predicted (Figure 
S2A), possibly because the sgRNA sequence used in the 
present study was provided commonly by all of three online 
sgRNA design programs. Sequencing analysis demonstrated 
that no mutation was introduced into the gene, suggesting 
that CD44‐KO cells are valid to study the function of CD44s 
(Figure S2B).
Several CSC markers increase cellular antioxidant ca-
pacity.18,28,29 In colorectal carcinoma and neuroglioma cells, 
CD44s was reported to enhance NADPH production by ac-
tivating the pentose‐phosphate pathway.34 This led to an in-
crease in cellular GSH content because glutathione reductase 
reduces GSSG by using NADPH. CD44v reportedly also in-
creased cellular GSH content by enhancing its biosynthesis 
in gastric cancer.18 Because CD44s lacks the domain inter-
acting with xCT, which is required for the enhancement of 
GSH biosynthesis by CD44v, it has been unclear whether 
CD44s regulates redox status in HCC. Our data demonstrated 
that CD44s increases cellular antioxidant capacity by upreg-
ulating antioxidant enzymes, TXN and GPX1. The mech-
anism underlying how CD44s regulates GPX1 and TXN 
expression remains unknown. It was reported that a CD44s 
ligand, hyaluronic acid, upregulates and activates nuclear 
factor erythroid 2‐related factor 2 (NRF2) in bovine articular 
chondrocytes and then activated NRF2 further induces the 
expression of antioxidant enzymes including GPX1.35 The 
CD44s‐induced activation of NRF2 was also observed in a 
doxorubicin‐resistant breast cancer cell line, which possesses 
CSC‐like characteristics and dominantly expresses CD44s.36 
It was demonstrated that NRF2 activation protects the breast 
cancer cells from oxidative stress and anticancer drugs.36
Among several isozymes of GPXs known in mammals, 
GPX1 is the most ubiquitously and abundantly expressed in 
most tissues, but has a limited role under a healthy condition 
because no obvious phenotype was observed in Gpx1 knock‐
out mice.37 It was reported that docosahexaenoic acid (DHA) 
sensitized MDA‐MB‐231 breast cancer cell to doxorubicin 
by suppressing GPX1 activity.38 Of note, although oxidative 
stress was increased in the cells treated with doxorubicin and 
DHA, cellular GSH content was significantly increased.38 A 
similar observation was also made in Caco‐2 cell monolayer, 
where GSH content was increased by treating with mercap-
tosuccinate, a GPX inhibitor.30 In accordance with these re-
ports, we also observed increased GSH content and GSH/
GSSG ratio in CD44‐KO cells, suggesting that CD44s, un-
like CD44v, enhances the consumption of GSH by activating 
GPX1. TXN is also another important antioxidant enzyme 
in normal and cancer cells.39 Increased oxidative stress due 
to the downregulation of GPX1 and TXN might contribute 
to sensitization of CD44‐KO cells to 5‐FU and sorafenib at 
least in part because both drugs increase oxidative stress in 
cells.40,41
We found that GPX1 expression was significantly in-
creased in HCC tissues (data not shown). However, CD44 
makes little, if any, contribution to this upregulation at least 
in human HCC tissues, unlike in HuH7 cells, because no 
correlation between CD44 and GPX1 was observed (Figure 
7). On the other hand, NOTCH3 expression was correlated 
with CD44 in the HCC tissues (Figure 7). In mammals, four 
NOTCH receptors (NOTCH1‐NOTCH4) are known, and 
reported to play roles in development, differentiation, and 
tumorigenesis.42 It has been demonstrated that NOTCH2 
is involved in self‐renewal of CSCs in HCC.43,44 NOTCH3 
also reportedly regulates the stemness of CSCs of HCC.45,46 
Although no functional relationship between CD44s and 
NOTCH3 in HCC has been reported, Ma Y, et al observed 
that NOTCH3 was upregulated in nonsmall cell lung cancer 
tissues from chemoresistant patients and was positively as-
sociated with CD44.47 In addition, it was demonstrated that 
Her2‐negative breast tumors showed increased expression of 
NOTCH1 and NOTCH3.48 Knock‐down of NOTCH3 sensi-
tized breast cancer cells to radiation more than did NOTCH1, 
and this effect was more prominent in CD44‐positive cells 
than in CD44‐negative cells.48 In the present study, it was 
observed that the upregulation of NOTCH3 mRNA was 
markedly suppressed in CD44‐KO cells while there was no 
significant change in the expression of NOTCH3 activators 
(Figure 6B,C). However, there was a discrepancy between 
mRNA and NICD protein expression levels of NOTCH3 in 
F I G U R E  7  Correlation analysis of 
CD44 expression with NOTCH3 (right) 
and GPX1 (left) in HCC clinical samples. 
Spearman's coefficients (ρ) and P values are 
shown
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the spheroids of HuH7 and CD44‐KO cells (Figure 6B,D). 
These results imply that CD44 deficiency may impair the 
cleavage of NOTCH3 as well as its transcription. It is possi-
ble that other factors, such as ADAM17,49 might play a role 
in the activation of NOTCH3 in the downstream of CD44 
in HCC cells. Although the detailed molecular mechanism 
remains to be clarified, our data suggest that NOTCH3 is 
an important mediator for the induction and maintenance of 
CSCs by CD44s in HCC as in other cancers.
The limitation of the present study is that we investigated 
the function of CD44s in one HCC cell line. However, al-
though further studies should be carried out, the gene ex-
pression analysis of our cohort suggests that there is a 
close relationship between CD44 and NOTCH3 in HCC. 
Interestingly, although the target genes differed among cell 
lines, the upregulation of NOTCH3 as well as its target genes 
was observed in the spheroids of other HCC cell lines in-
cluding HLE, HuH6, and PLC/PRF/5, whereas the NOTCH3 
pathway was unlikely activated in those of HLF and HepG2 
cells (Figure S3C). In addition, NOTCH3 was shown to be 
critical for the cancer stemness of HuH7 cells (Figure S3B). 
Considering these observations along with the significant up-
regulation of NOTCH3 in HCC tissues, NOTCH3 would be 
the therapeutic target of precision medicine for HCC.
In conclusion, we demonstrated that CD44s plays an im-
portant role in maintaining CSCs of HuH7 cells and regu-
lates oxidative stress in HuH7 cells. CD44‐KO cells showed 
marked downregulation of NOTCH3 and GPX1, both of 
which are significantly increased in HCC tissues, compared 
with adjacent nontumor tissues. In addition, CD44 expression 
in HCC tissues was significantly correlated with NOTCH3 
expression, suggesting that CD44 regulates CSC properties 
via NOTCH3. Because CD44 is expressed in normal cells as 
well, NOTCH3 may be a better therapeutic target for CSC‐
directed therapy of CD44‐positive HCC. The clarification of 
molecular mechanism underlying CD44s‐induced NOTCH3 
will deepen our understanding of CSCs in HCC and will pro-
vide new insights into the development and recurrence of 
HCC.
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